Fred Aslan, President and CEO at Artiva Biotherapeutics, Inc. (ARTV), sold 12,722 shares at $3.38 ($42K) on 2025-11-17, disclosed to the SEC on 2025-11-17.
Scheduled sale ($42k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.25 | 6,347 | $21K | 48.9% |
| 2 | $3.38 | 6,375 | $22K | 51.1% |
| Total | $3.32 avg | 12,722 | $42K | 100% |
| Filing → |
| ARTV | SELL | 2026-05-19 | $244K | — | Filing → |
| ARTV | SELL | 2025-12-15 | $19K | — | Filing → |
| ARTV | SELL | 2025-10-17 | $153K | — | Filing → |